KimAnna(Reiss)Reiss BinderMD

Oncology • Philadelphia, PA

Assistant Professor, Hematology-Oncology University of Pennsylvania

Join to view full profile

Dr. Reiss Binder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reiss Binder's full profile

Already have an account?

Office
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone+1 215-615-5858

Fax+1 410-662-4646

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
Johns Hopkins UniversityResidency, Internal Medicine, 2008 - 2011
Pennsylvania State University College of MedicineClass of 2008

Certifications & Licensure

PA State Medical License 2015 - 2024
MD State Medical License 2011 - 2015
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Career Development Award ASCO, 2017

Clinical Trials

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) Start of enrollment: 2017 Mar 30
Completed
Phase 1
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Start of enrollment: 2017 Sep 05
Terminated
Phase 2

Publications & Presentations

PubMed

45 citations
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Kim A Reiss, Rosemarie Mick, Ursina Teitelbaum, Mark O'Hara, Charles Schneider
The Lancet. Oncology. 2022-08-01
8 citations
Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Shun Yu, Ronac Mamtani, Mark H. O'Hara, P. J. O'Dwyer, Ofer Margalit
Clinical Colorectal Cancer. 2021-01-22
2 citations
The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
Timothy J Brown, Arielle Yablonovitch, Jacob E Till, Jennifer Yen, Lesli A Kiedrowski
Clinical Cancer Research. 2023-12-15

Lectures

A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-ba...
2019 ASCO Annual Meeting - 6/1/2019